[{"orgOrder":0,"company":"Bio-Techne","sponsor":"Luminary Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"LMY-920","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bio-Techne","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Techne \/ Luminary Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Techne \/ Luminary Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Bio-Techne

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          APS Symposium
                          Not Confirmed
                          APS Symposium
                          Not Confirmed

                          Details : Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster™. Luminary Therapeutics will use TcBuster™ in their LMY-920 program, a BAFF-CAR-T product. Luminary Therapeutics plans to file an IND with the FDA later this calendar year.

                          Product Name : LMY-920

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          February 23, 2021

                          Lead Product(s) : LMY-920

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Luminary Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank